## **CLAIMS**

We claim:

## 1. A compound of Formula I

5

wherein:

Q is CH or N;

10  $R^1$  is tetrazolyl, MeCONHSO<sub>2</sub>-, PhCONHSO<sub>2</sub>-,  $R^5$ O<sub>2</sub>C(CH<sub>2</sub>)<sub>0-3</sub>CONHSO<sub>2</sub>-,

R<sup>2</sup> is  $\stackrel{h^6}{\mathsf{h}^6}$  ,  $-\mathsf{CH}_2\mathsf{A}\mathsf{A}^1$ ,  $-\mathsf{CHPh}_2$  ,  $-\mathsf{CH}_2\mathsf{CO}(4\text{-FPh})$ ,  $-\mathsf{CH}_2\mathsf{CO}(4\text{-CF}_3\mathsf{Ph})$ , or  $-\mathsf{CH}_2\mathsf{CONp}$  where Np is naphthyl;

15 R<sup>3</sup> is C<sub>5-7</sub>cycloalkyl;

R4 is hydrogen, Ar2, or Ar3;

Ar<sup>1</sup> is selected from the following group: phenyl, halophenyl,

Ar² is phenyl, naphthyl, or biphenyl, optionally substituted with 1-3 substituents

selected from the group comprising halogen, C<sub>1-6</sub> alkyl, hydroxyC<sub>1-6</sub>alkyl,

C<sub>1-6</sub>alkoxy, C<sub>1-6</sub>sulfoxy, C<sub>1-2</sub>perfluoroalkyl, hydroxy, formyl,

C<sub>1-6</sub>alkylcarbonyl, cyano, nitro, C<sub>1-6</sub>alkylamido, CO<sub>2</sub>R<sup>5</sup>, CONR<sup>5</sup>R<sup>5</sup>,

C<sub>1-6</sub>alkylsulfonamido, and dioxolane;

Ar³ is thienyl, furanyl, pyrrolyl, benzothiophenyl, benzofuranyl, indolyl,

quinolinyl, or pyrimidinyl optionally substituted with 1-2 substituents
selected from the group comprising C<sub>1-6</sub>alkyl, formyl, acetoxy,
trifluoroacetoxy, and t-butoxycarbonyl;

R5 is hydrogen or C1-6alkyl;

20

R<sup>6</sup> is halogen, methoxy, CO<sub>2</sub>R<sup>5</sup> or CONR<sup>7</sup>R<sup>8</sup>;

15 R<sup>7</sup> and R<sup>8</sup> are independently hydrogen, C<sub>1-6</sub>alkyl, -CH(Me)CO<sub>2</sub>R<sup>5</sup>,

$$-(CH_2)_{1:3}CO_2R^5, -(CH_2)_{1:3}CONR^5R^5, -(CH_2)_{1:3}OH, \xrightarrow{\xi} CO_2R^5 \\ , \\ Or \xrightarrow{\xi} CO_2R^5 \\ ;$$

or R<sup>7</sup> and R<sup>8</sup> taken together with the nitrogen to which they are attached form pyrrolidine, morpholine, piperidine, 4-hydroxypiperidine, piperazine, or 4-methylpiperazine;

or a pharmaceutically acceptable salt, solvate, or prodrug thereof.

A compound of claim 1 wherein R<sup>3</sup> is cyclohexyl.



- 3. A compound of claim 1 wherein R<sup>1</sup> is tetrazolyl and R<sup>2</sup> is
- A compound of claim 3 wherein R<sup>4</sup> is Ar<sup>2</sup>.
  - 5. A compound of claim 4 wherein R<sup>3</sup> is cyclohexyl.
  - 6. A compound of claim 3 wherein R<sup>4</sup> is Ar<sup>3</sup>.
- 10 7. A compound of claim 6 wherein R<sup>3</sup> is cyclohexyl.
  - 8. A compound of claim 3 wherein R<sup>4</sup> is hydrogen.
  - A compound of claim 8 wherein R<sup>3</sup> is cyclohexyl.
  - A compound of claim 1 wherein R<sup>2</sup> is -CH<sub>2</sub>Ar<sup>1</sup>.
    - 11. A compound of claim 10 wherein R<sup>3</sup> is cyclohexyl.
- 20 12. A composition useful for treating hepatitus C comprising a therapeutic amount of a compound of claim 1 and a pharmaceutically acceptable carrier.
  - 13. A method for treating hepatitus C comprising administering a therapeutically effective amount of a compound of claim 1 to a patient.

15

5